HIF Inhibitors: Status of Current Clinical Development
Sign Up to like & getrecommendations! Published in 2019 at "Current Oncology Reports"
DOI: 10.1007/s11912-019-0752-z
Abstract: Purpose of ReviewIn this review, the importance of the hypoxia inducible factor (HIF) pathway in tumorigenesis and cancer treatment outcomes will be discussed. The outcomes of phase II and III clinical trials of direct HIF… read more here.
Keywords: hif; current clinical; inhibitors status; status current ... See more keywords
Status of the Current Treatment Options and Potential Future Targets in Uterine Leiomyosarcoma: A Review
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14051180
Abstract: Simple Summary Uterine leiomyosarcoma (uLMS) is a rare and aggressive mesenchymal malignancy. Although approximately 65% of patients are diagnosed in stage I, more than 50% have relapsed disease, and effective therapies for recurrent and advanced… read more here.
Keywords: brca2 mutations; review; uterine leiomyosarcoma; status current ... See more keywords